Project places Shepparton at the forefront of plant-based medicine production and distribution 

MMj daily reports that Cannatrek’s Shepparton facility has received Good Manufacturing Practice (GMP) accreditation from the Therapeutic Goods Administration (TGA). This recognition is part of Cannatrek’s $17 million investment in the Shepparton region, backed by the Victorian Government. CEO Tommy Huppert emphasised the patient-first approach and recognised how the accreditation will enhance in-house production and quality control. Over the next three years, the facility is predicted to create more than 70 regional jobs and expand manufacturing opportunities. 

Read more:

Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.